

PRECEPTORSHIP PROGRAMME

METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

SINGAPORE

19-20 SEPTEMBER 2018

Co-Chairs Joaquim Bellmunt, ES
 Ravindran Kanesvaran, SG

ESMO PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Singapore
19-20 September 2018

CO-CHAIRS: Joaquim Bellmunt, Spain
Ravindran Kanesvaran, Singapore

SPEAKERS: Melvin Lee Kiang Chua, Singapore
Lui Shiong Lee, Singapore
Nye-Thane Ngo, Singapore
Chee Keong Toh, Singapore
Naveen Vasudev, United Kingdom

LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer

ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 19 September 2018

09:00-09:15 15'	Opening and welcome	
15'	Welcome from ESMO - Objectives and scientific introduction	Joaquim Bellmunt, ES Ravindran Kanesvaran, SG
09:15-10:30 75'	SESSION 1 - Personalized therapy in bladder cancer and Renal Cell Cancer (RCC)	Chair: Joaquim Bellmunt, ES
20'	The search for biomarkers in bladder cancer	Joaquim Bellmunt, ES
20'	The search for biomarkers in resected RCC	Naveen Vasudev, UK
20'	The search for biomarkers in mRCC	Naveen Vasudev, UK
15'	Discussion	Faculty
10:30-11:00	Coffee break	
11:00-12:35 95'	SESSION 2 - Multidisciplinary approach in metastatic urothelial cancer and RCC	Chair: Melvin Lee Kiang Chua, SG
15'	The role of surgery in metastatic bladder cancer	Lui Shiong Lee, SG
20'	RCC: Surgery in metastatic disease	Lui Shiong Lee, SG
20'	Radiotherapy in metastatic urothelial cancer and RCC	Melvin Lee Kiang Chua, SG
10'	Discussion	Faculty
2x15'	2 x Participant clinical case discussion	Faculty
12:35-13:30	Lunch	
13:30-15:20 110'	SESSION 3 - Metastatic disease: Systemic therapy	Chair: Ravindran Kanesvaran, SG
15'	Metastatic bladder cancer: Chemotherapy	Chee Keong Toh, SG
15'	mRCC: Anti-angiogenic therapy	Ravindran Kanesvaran, SG
20'	Metastatic bladder cancer: Immunotherapy	Joaquim Bellmunt, ES
20'	mRCC: Immunotherapy	Naveen Vasudev, UK
10'	Discussion	Faculty
2x15'	2 x Participant clinical case discussion	Faculty
15:20-15:50	Coffee break	
15:50-17:00 70'	SESSION 4 - Debate of the day	Chair: Naveen Vasudev, UK
25'	Systemic chemotherapy is the standard for metastatic urothelial cancer: YES/NO	Chee Keong Toh, SG Joaquim Bellmunt, ES
15'	Discussion	Faculty
2x15'	2 x Participant clinical case discussion	Faculty
19:00	Dinner	

Thursday, 20 September 2018

09:00-10:10 70'	SESSION 5 - Pathology and molecular pathology	Chair: Joaquim Bellmunt, ES
20'	Bladder cancer	Nye-Thane Ngo, SG
20'	Kidney cancer	Nye-Thane Ngo, SG
15'	Clinical application	Chee Keong Toh, SG
15'	Discussion	Faculty
10:10-10:40	Coffee break	
10:40-11:50 70'	SESSION 6 - Side effects	Chair: Ravindran Kanesvaran, SG
2x15'	2 x Participant clinical case discussion	Faculty
10'	Chemotherapy	Ravindran Kanesvaran, SG
15'	Tyrosine Kinase Inhibitors and mTOR Inhibitors	Naveen Vasudev, UK
15'	Immunotherapy	Joaquim Bellmunt, ES
11:50-12:05 15'	Conclusion and farewell	Joaquim Bellmunt, ES Ravindran Kanesvaran, SG
12:05-13:05	Lunch	

Note: Each 15 minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion